PRESS RELEASE published on 01/24/2024 at 13:00, 2 years 2 months ago PHBI - Pharmagreen Signs Supply Contract and Trade Marked Name Use of SierraSil(R) in Its’ Nutraceutical Formulations Pharmagreen Biotech, Inc., (OTC PINK:PHBI) signed a supply agreement with SierraSil® Health Inc., allowing the incorporation of SierraSil® minerals into its MaxGenomic® formulations. This agreement aims to promote joint tissue detoxification and aid DNA repair with the use of beta-glucans, polysaccharides, and minerals. Pharmagreen is also preparing to launch new gummy products and a pre-workout one-shot formula, all sugar-free and designed to promote wellness. The company's goal is to achieve positive cash flow by year-end and continue developing innovative nutraceutical products. Pharmagreen Biotech Inc SierraSil Minerals MaxGenomic Formulations Nutraceutical Products Wellness Benefits
Published on 04/09/2026 at 16:00, 57 minutes ago Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 2 hours 17 minutes ago Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 2 hours 57 minutes ago Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 3 hours 27 minutes ago Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 13:30, 3 hours 27 minutes ago ESGold Advances Toward Production and Exploration Drilling as Mill Buildout Progresses in Parallel
Published on 04/09/2026 at 15:40, 1 hour 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 1 hour 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/09/2026 at 15:39, 1 hour 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 04/09/2026 at 15:57, 59 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 9 hours 57 minutes ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 22 hours 55 minutes ago Publication of the 2025 Universal Registration Document
Published on 04/08/2026 at 17:45, 23 hours 12 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 04/08/2026 at 12:58, 1 day 3 hours ago EURAZEO IS ASSIGNED A BBB CREDIT RATING (STABLE OUTLOOK) BY S&P AND A BBB CREDIT RATING (STABLE OUTLOOK) BY FITCH